{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:11:20Z","timestamp":1765807880322,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00404-020-05918-3","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:04:46Z","timestamp":1609632286000},"page":"1121-1130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["What happens after randomised controlled trials? Uterine fibroids and ulipristal acetate: systematic review and meta-analysis of \"real-world\" data"],"prefix":"10.1007","volume":"303","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7540-3179","authenticated-orcid":false,"given":"Neha","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Egbase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sideris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Funlayo","family":"Odejinmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,2]]},"reference":[{"issue":"4","key":"5918_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/ajcp\/94.4.435","volume":"94","author":"SF Cramer","year":"1990","unstructured":"Cramer SF, Patel A (1990) The frequency of uterine leiomyomas. Am J Clin Pathol 94(4):435\u2013438. https:\/\/doi.org\/10.1093\/ajcp\/94.4.435","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"5918_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.fertnstert.2007.01.093","volume":"87","author":"WH Parker","year":"2007","unstructured":"Parker WH (2007) Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril 87(4):725\u2013736. https:\/\/doi.org\/10.1016\/j.fertnstert.2007.01.093","journal-title":"Fertil Steril"},{"key":"5918_CR3","doi-asserted-by":"publisher","first-page":"h4887","DOI":"10.1136\/bmj.h4887","volume":"351","author":"MA Lumsden","year":"2015","unstructured":"Lumsden MA, Hamoodi I, Gupta J, Hickey M (2015) Fibroids: diagnosis and management. BMJ 351:h4887. https:\/\/doi.org\/10.1136\/bmj.h4887 (Published 2015 Oct 13)","journal-title":"BMJ"},{"issue":"6","key":"5918_CR4","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0029-7844(97)00534-6","volume":"90","author":"LM Marshall","year":"1997","unstructured":"Marshall LM, Spiegelman D, Barbieri RL et al (1997) Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 90(6):967\u2013973","journal-title":"Obstet Gynecol"},{"issue":"3","key":"5918_CR5","doi-asserted-by":"publisher","first-page":"211.e1","DOI":"10.1016\/j.ajog.2011.12.002","volume":"206","author":"ER Cardozo","year":"2012","unstructured":"Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH (2012) The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol 206(3):211.e1-211.e2119. https:\/\/doi.org\/10.1016\/j.ajog.2011.12.002","journal-title":"Am J Obstet Gynecol"},{"key":"5918_CR6","doi-asserted-by":"publisher","first-page":"2414609","DOI":"10.1155\/2018\/2414609","volume":"2018","author":"TD Lewis","year":"2018","unstructured":"Lewis TD, Malik M, Britten J, San Pablo AM, Catherino WH (2018) A comprehensive review of the pharmacologic management of uterine leiomyoma. Biomed Res Int. 2018:2414609. https:\/\/doi.org\/10.1155\/2018\/2414609 (Published 2018 Jan 28)","journal-title":"Biomed Res Int."},{"key":"5918_CR7","doi-asserted-by":"publisher","first-page":"1374821","DOI":"10.1155\/2018\/1374821","volume":"2018","author":"T Rabe","year":"2018","unstructured":"Rabe T, Saenger N, Ebert AD et al (2018) Selective progesterone receptor modulators for the medical treatment of uterine fibroids with a focus on ulipristal acetate. Biomed Res Int. 2018:1374821. https:\/\/doi.org\/10.1155\/2018\/1374821 (Published 2018 Jun 24 [published correction appears in Biomed Res Int. 2018 Nov 28;2018:6124628])","journal-title":"Biomed Res Int."},{"issue":"2","key":"5918_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/ijgo.12868","volume":"146","author":"M Ghonim","year":"2019","unstructured":"Ghonim M, Magdy R, Sabbour M, Ghonim M, Nabhan A (2019) A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids. Int J Gynaecol Obstet 146(2):141\u2013148. https:\/\/doi.org\/10.1002\/ijgo.12868","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"5918_CR9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa1103180","volume":"366","author":"J Donnez","year":"2012","unstructured":"Donnez J, Tomaszewski J, V\u00e1zquez F et al (2012) Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 366(5):421\u2013432. https:\/\/doi.org\/10.1056\/NEJMoa1103180","journal-title":"N Engl J Med"},{"issue":"5","key":"5918_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1056\/NEJMoa1103182","volume":"366","author":"J Donnez","year":"2012","unstructured":"Donnez J, Tatarchuk TF, Bouchard P et al (2012) Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 366(5):409\u2013420. https:\/\/doi.org\/10.1056\/NEJMoa1103182","journal-title":"N Engl J Med"},{"issue":"3","key":"5918_CR11","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1016\/j.fertnstert.2016.08.005","volume":"106","author":"J Simon","year":"2016","unstructured":"Simon J, Catherino W, Segars J, Blakesley R, Chan A, Sniukiene V, Al-Hendy A (2016) First US-based phase 3 study of ulipristal acetate (UPA) for symptomatic uterine fibroids (UF): results of VENUS-I. Fertil Steril 106(3):e376. https:\/\/doi.org\/10.1016\/j.fertnstert.2016.08.005","journal-title":"Fertil Steril"},{"issue":"3","key":"5918_CR12","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/j.fertnstert.2017.07.096","volume":"108","author":"J Liu","year":"2017","unstructured":"Liu J, Soper D, Lukes A, Gee P, Kimble T, Kroll R et al (2017) VENUS II: the second us-based phase 3 study of ulipristal acetate (UPA) for treatment of symptomatic uterine fibroids (UF). Fertil Steril 108(3):e27\u2013e28. https:\/\/doi.org\/10.1016\/j.fertnstert.2017.07.096","journal-title":"Fertil Steril"},{"issue":"7","key":"5918_CR13","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jval.2017.03.008","volume":"20","author":"A Makady","year":"2017","unstructured":"Makady A, de Boer A, Hillege H, Klungel O, Goettsch W, (on behalf of GetReal Work Package 1) (2017) What is real-world data? A review of definitions based on literature and stakeholder interviews. Value Health. 20(7):858\u2013865. https:\/\/doi.org\/10.1016\/j.jval.2017.03.008","journal-title":"Value Health."},{"issue":"7","key":"5918_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrd3501","volume":"10","author":"HG Eichler","year":"2011","unstructured":"Eichler HG, Abadie E, Breckenridge A et al (2011) Bridging the efficacy-effectiveness gap: a regulator\u2019s perspective on addressing variability of drug response. Nat Rev Drug Discov 10(7):495\u2013506. https:\/\/doi.org\/10.1038\/nrd3501 (Published 2011 Jul 1)","journal-title":"Nat Rev Drug Discov"},{"key":"5918_CR15","unstructured":"Increasing use of health and social care data in guidance development. (2019). Retrieved from https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/nice-guidelines\/how-we-develop-nice-guidelines\/data-and-analytics-statement-of-intent. Accessed 26 Apr 2020"},{"key":"5918_CR16","unstructured":"Association of The British Pharmaceutical Industry. 2011. Demonstrating Value with Real World data. Retrieved from: https:\/\/www.abpi.org.uk\/publications\/real-world-data. Accessed 23 May 2020"},{"issue":"3","key":"5918_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/1745505717740218","volume":"13","author":"F Odejinmi","year":"2017","unstructured":"Odejinmi F, Oliver R, Mallick R (2017) Is ulipristal acetate the new drug of choice for the medical management of uterine fibroids? Res ipsa loquitur? Womens Health (Lond) 13(3):98\u2013105. https:\/\/doi.org\/10.1177\/1745505717740218","journal-title":"Womens Health (Lond)"},{"issue":"5","key":"5918_CR18","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1097\/AOG.0000000000002942","volume":"132","author":"JH Liu","year":"2018","unstructured":"Liu JH, Soper D, Lukes A et al (2018) Ulipristal acetate for treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 132(5):1241\u20131251. https:\/\/doi.org\/10.1097\/AOG.0000000000002942","journal-title":"Obstet Gynecol"},{"issue":"1","key":"5918_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/aogs.13713","volume":"99","author":"I de Milliano","year":"2020","unstructured":"de Milliano I, Huirne JAF, Thurkow AL et al (2020) Ulipristal acetate vs gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy (MYOMEX trial): short-term results of a double-blind randomized controlled trial. Acta Obstet Gynecol Scand 99(1):89\u201398. https:\/\/doi.org\/10.1111\/aogs.13713","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"3","key":"5918_CR20","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.jmig.2017.10.016","volume":"25","author":"A Murji","year":"2018","unstructured":"Murji A, Wais M, Lee S, Pham A, Tai M, Liu G (2018) A multicenter study evaluating the effect of ulipristal acetate during myomectomy. J Minim Invasive Gynecol 25(3):514\u2013521. https:\/\/doi.org\/10.1016\/j.jmig.2017.10.016","journal-title":"J Minim Invasive Gynecol"},{"issue":"5","key":"5918_CR21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1080\/01443615.2017.1287687","volume":"37","author":"BF Chen","year":"2017","unstructured":"Chen BF, Powell MC, O\u2019Beirne C (2017) An observation study of the clinical evaluation of symptom relief and side effects associated with taking ulipristal acetate (esmya) including its effect on pre-menstrual syndrome. J Obstet Gynaecol 37(5):645\u2013648. https:\/\/doi.org\/10.1080\/01443615.2017.1287687","journal-title":"J Obstet Gynaecol"},{"issue":"5","key":"5918_CR22","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jmig.2017.02.025","volume":"24","author":"L Luketic","year":"2017","unstructured":"Luketic L, Shirreff L, Kives S et al (2017) Does ulipristal acetate affect surgical experience at laparoscopic myomectomy? J Minim Invasive Gynecol 24(5):797\u2013802. https:\/\/doi.org\/10.1016\/j.jmig.2017.02.025","journal-title":"J Minim Invasive Gynecol"},{"issue":"3","key":"5918_CR23","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/ijgo.12968","volume":"147","author":"J Verguts","year":"2019","unstructured":"Verguts J, Godin PA, De Vree B et al (2019) Effect on surgical decisions: ulipristal acetate as key player in Belgian phase IV registration trial. Int J Gynaecol Obstet 147(3):339\u2013343. https:\/\/doi.org\/10.1002\/ijgo.12968","journal-title":"Int J Gynaecol Obstet"},{"issue":"9","key":"5918_CR24","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1002\/jum.14573","volume":"37","author":"S Baggio","year":"2018","unstructured":"Baggio S, Pomini P, Galeone F et al (2018) Influence of ulipristal acetate therapy on uterine fibroid-related symptoms and on uterine and fibroid volumes and vascularity indices assessed by ultrasound. J Ultrasound Med 37(9):2215\u20132223. https:\/\/doi.org\/10.1002\/jum.14573","journal-title":"J Ultrasound Med"},{"key":"5918_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejogrb.2017.12.033","volume":"222","author":"JL Brun","year":"2018","unstructured":"Brun JL, Rajaonarison J, Froeliger A, Monseau-Thiburce AC, Randriamboavonjy R, Vogler A (2018) Outcome of patients with uterine fibroids after 3-month ulipristal acetate therapy. Eur J Obstet Gynecol Reprod Biol 222:13\u201318. https:\/\/doi.org\/10.1016\/j.ejogrb.2017.12.033","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"5918_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejogrb.2018.03.026","volume":"224","author":"BS Yun","year":"2018","unstructured":"Yun BS, Seong SJ, Jung YW et al (2018) Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate. Eur J Obstet Gynecol Reprod Biol 224:133\u2013136. https:\/\/doi.org\/10.1016\/j.ejogrb.2018.03.026","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"5918_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejogrb.2016.11.003","volume":"208","author":"H Fernandez","year":"2017","unstructured":"Fernandez H, Schmidt T, Powell M, Costa AP, Arriagada P, Thaler C (2017) Real-world data of 1473 patients treated with ulipristal acetate for uterine fibroids: premya study results. Eur J Obstet Gynecol Reprod Biol 208:91\u201396. https:\/\/doi.org\/10.1016\/j.ejogrb.2016.11.003","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"2","key":"5918_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/GMIT.GMIT_79_18","volume":"8","author":"R Mallick","year":"2019","unstructured":"Mallick R, Oxley S, Odejinmi F (2019) The use of ulipristal acetate (esmya) prior to laparoscopic myomectomy: help or hindrance? Gynecol Minim Invasive Ther 8(2):62\u201366. https:\/\/doi.org\/10.4103\/GMIT.GMIT_79_18","journal-title":"Gynecol Minim Invasive Ther"},{"key":"5918_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejogrb.2016.08.021","volume":"205","author":"S Ferrero","year":"2016","unstructured":"Ferrero S, Alessandri F, Vellone VG, Venturini PL, Leone Roberti Maggiore U (2016) Three-month treatment with ulipristal acetate prior to laparoscopic myomectomy of large uterine myomas: a retrospective study. Eur J Obstet Gynecol Reprod Biol 205:43\u201347. https:\/\/doi.org\/10.1016\/j.ejogrb.2016.08.021","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"3","key":"5918_CR30","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jmig.2015.12.002","volume":"23","author":"S Ferrero","year":"2016","unstructured":"Ferrero S, Racca A, Tafi E, Alessandri F, Venturini PL, Leone Roberti Maggiore U (2016) Ulipristal acetate before high complexity hysteroscopic myomectomy: a retrospective comparative study. J Minim Invasive Gynecol. 23(3):390\u2013395. https:\/\/doi.org\/10.1016\/j.jmig.2015.12.002","journal-title":"J Minim Invasive Gynecol."},{"issue":"6","key":"5918_CR31","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/01443615.2017.1405926","volume":"38","author":"N Woodhead","year":"2018","unstructured":"Woodhead N, Pounds R, Irani S, Pradhan P (2018) Ulipristal acetate for uterine fibroids: 2 years of real-world experience in a UK hospital. J Obstet Gynaecol 38(6):813\u2013817. https:\/\/doi.org\/10.1080\/01443615.2017.1405926","journal-title":"J Obstet Gynaecol"},{"issue":"1","key":"5918_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5468\/ogs.2017.60.1.69","volume":"60","author":"MJ Lee","year":"2017","unstructured":"Lee MJ, Yun BS, Seong SJ et al (2017) Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist. Obstet Gynecol Sci 60(1):69\u201373. https:\/\/doi.org\/10.5468\/ogs.2017.60.1.69","journal-title":"Obstet Gynecol Sci"},{"issue":"2","key":"5918_CR33","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.fertnstert.2014.10.038","volume":"103","author":"J Donnez","year":"2015","unstructured":"Donnez J, Hudecek R, Donnez O et al (2015) Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril 103(2):519\u201327.e3. https:\/\/doi.org\/10.1016\/j.fertnstert.2014.10.038","journal-title":"Fertil Steril"},{"key":"5918_CR34","unstructured":"Suspension of ulipristal acetate for uterine fibroids during ongoing EMA review liver injury risk -European Medicines Agency (2020). Retrieved from https:\/\/www.ema.europa.eu\/en\/news\/suspension-ulipristal-acetate-uterine-fibroids-during-ongoing-ema-review-liver-injury-risk. Accessed 8 Apr 2020"},{"key":"5918_CR35","unstructured":"Esmya (2018) Retrieved from https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/esmya#key-facts-section. Accessed 15 Nov 2020"},{"key":"5918_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010770.pub2","author":"A Murji","year":"2017","unstructured":"Murji A, Whitaker L, Chow TL, Sobel ML (2017) Selective progesterone receptor modulators (SPRMs) for uterine fibroids. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD010770.pub2 (Art. No.: CD010770)","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05918-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-020-05918-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05918-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T14:07:33Z","timestamp":1618668453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-020-05918-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,2]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["5918"],"URL":"https:\/\/doi.org\/10.1007\/s00404-020-05918-3","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"type":"print","value":"0932-0067"},{"type":"electronic","value":"1432-0711"}],"subject":[],"published":{"date-parts":[[2021,1,2]]},"assertion":[{"value":"1 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}